Abstract
No public abstract is available from the verified source records.
Sara Alrawashdeh, Gazia Buzaakuk, Raghd Obidat, Adam R. Karpf, Carlos A. Velázquez-Martínez
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Forkhead transcription factors: key players in health and disease
10.1016/j.tig.2011.03.003 · 2011
Toward a mechanistic understanding of DNA binding by forkhead transcription factors and its perturbation by pathogenic mutations
10.1093/nar/gkab807 · 2021
Kaestner KH Fox transcription factors: from development to disease
10.1242/dev.112672 · 2016
Structure of the forkhead domain of FOXA2 bound to a complete DNA consensus site
10.1021/acs.biochem.7b00211 · 2017
FOXA1 and FOXA2: the regulatory mechanisms and therapeutic implications in cancer
10.1038/s41420-024-01936-1 · 2024
An order-to-disorder structural switch activates the FoxM1 transcription factor
10.7554/elife.46131 · 2019
Ser715 phosphorylation induces β-hairpin unfolding and destabilization of FOXM1 autoinhibition
10.1021/acs.jcim.6c01772 · 2026
Forkhead box proteins: tuning forks for transcriptional harmony
10.1038/nrc3539 · 2013
Forkhead box transcription factors: double-edged swords in cancer
10.1158/0008-5472.can-21-3371 · 2022
Targeting of the FOXM1 oncoprotein by E3 ligase-assisted degradation
10.1021/acs.jmedchem.1c01069 · 2021
FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer
10.1038/s41467-024-49234-9 · 2024
Redirecting the pioneering function of FOXA1 with covalent small molecules
10.1016/j.molcel.2024.09.024 · 2024
Joint sequence & chromatin neural networks characterize the differential abilities of Forkhead transcription factors to engage inaccessible chromatin
2023
10.1038/s41419-023-06177-1
10.1038/s41419-023-06177-1 · 2023
Role of Forkhead Box Class O proteins in cancer progression and metastasis
10.1016/j.semcancer.2017.07.007 · 2018
FOXO transcription factors in cancer development and therapy
10.1007/s00018-015-2112-y · 2016
Upregulated forkhead-box A3 elevates the expression of forkhead-box A1 and forkhead-box A2 to promote metastasis in esophageal cancer
2019
Opposing roles of FoxA1 and FoxA3 in intrahepatic cholangiocarcinoma progression
10.3390/ijms21051796 · 2020
Wnt activator FOXB2 drives the neuroendocrine differentiation of prostate cancer
10.1073/pnas.1906484116 · 2019
Therapeutically targeting cancers that overexpress FOXC1: a transcriptional driver of cell plasticity, partial EMT, and cancer metastasis
10.3389/fonc.2021.721959 · 2021
Unravelling the therapeutic potential of forkhead box proteins in breast cancer: an update (Review)
2024
The FOXC2 transcription factor: a master regulator of chemoresistance in cancer
10.1177/15330338231155284 · 2023
FOXC2 promotes oxaliplatin resistance by inducing epithelial-mesenchymal transition via MAPK/ERK signaling in colorectal cancer
10.2147/ott.s241367 · 2020
Dysregulated FOXM1 signaling in the regulation of cancer stem cells
10.1016/j.semcancer.2022.07.009 · 2022
FOXM1: a small fox that makes more tracks for cancer progression and metastasis
10.1016/j.semcancer.2023.03.007 · 2023
A narrative review of research progress on FoxM1 in breast cancer carcinogenesis and therapeutics
10.21037/atm-21-5271 · 2021
FOXP4-mediated induction of PTK7 activates the Wnt/β-catenin pathway and promotes ovarian cancer development
10.1038/s41419-024-06713-7 · 2024
Androgen-responsive FOXP4 is a target for endometrial carcinoma
10.1038/s42003-024-06433-w · 2024
Upregulation of FOXP4 in breast cancer promotes migration and invasion through facilitating EMT
10.2147/cmar.s191641 · 2019
FOXR2 is an epigenetically regulated pan-cancer oncogene that activates ETS transcriptional circuits
10.1158/0008-5472.can-22-0671 · 2022
Structurally oriented classification of FOXA1 alterations identifies prostate cancers with opposing clinical outcomes and distinct molecular and immunologic subtypes
10.1158/1078-0432.ccr-24-3471 · 2025
FOXO1 promotes cancer cell growth through MDM2-mediated p53 degradation
10.1016/j.jbc.2024.107209 · 2024
Nuclear FOXO1 promotes lymphomagenesis in germinal center B cells
10.1182/blood-2018-06-856203 · 2018
Mutations in the transcription factor FOXO1 mimic positive selection signals to promote germinal center B cell expansion and lymphomagenesis
10.1016/j.immuni.2021.07.009 · 2021
Diverse roles of FOXO family members in gastric cancer
10.4251/wjgo.v13.i10.1367 · 2021
FOXP3 as an X-linked tumor suppressor
2010
Identification of a tumor suppressor relay between the FOXP3 and the Hippo pathways in breast and prostate cancers
10.1158/0008-5472.can-10-3268 · 2011
Targeting FOXA1 and FOXA2 disrupts the lineage-specific oncogenic output program in prostate cancer
10.1016/j.celrep.2025.116324 · 2025
FoxO transcription factors in cancer metabolism
10.1016/j.semcancer.2018.01.004 · 2018
Role of FOXO transcription factors in cancer metabolism and angiogenesis
10.3390/cells9071586 · 2020
Genome-wide analysis of the FOXA1 transcriptional network identifies novel protein-coding and long noncoding RNA targets in colorectal cancer cells
10.1128/mcb.00224-20 · doi-reference
Invasive FoxM1 phosphorylated by PLK1 induces the polarization of tumor-associated macrophages to promote immune escape and metastasis, amplified by IFITM1
10.1186/s13046-023-02872-1 · doi-reference
FOXO signaling pathways as therapeutic targets in cancer
10.7150/ijbs.20052 · doi-reference
PROTAC-DB 3.0: an updated database of PROTACs with extended pharmacokinetic parameters
10.1093/nar/gkae768 · doi-reference
DiffPROTACs is a deep learning-based generator for proteolysis targeting chimeras
10.1093/bib/bbae358 · doi-reference
The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells
10.1126/scisignal.abn2707 · doi-reference
Targeting the undruggable: recent progress in PROTAC-induced transcription factor degradation
10.3390/cancers17111871 · doi-reference
PAX3::FOXO1-targeting PROTAC induces myogenic differentiation of fusion-positive Rhabdomyosarcoma cells
10.3390/cancers18152375 · doi-reference
A peptide-based PROTAC targeting FOXM1 suppresses fibrosis-associated hepatocarcinogenesis
10.7150/thno.129569 · doi-reference
Self-assembled peptide PROTAC prodrugs targeting FOXM1 for cancer therapy
10.1021/acs.molpharmaceut.5c00219 · doi-reference
A novel designed fully peptide-based PROTAC, FPP29, demonstrates its potent cytotoxic effects to liver cancer HCCLM3 cells by targeting FOXM1
10.1016/j.bioorg.2025.108626 · doi-reference
Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression
10.1186/s13046-022-02483-2 · doi-reference
Application of novel transcription factor machine learning model and targeted drug combination therapy strategy in triple negative breast cancer
10.3390/ijms241713497 · doi-reference
Repurposing masitinib mesylate as a novel FOXM1 inhibitor for the treatment of aggressive solid tumors: preclinical validation in human breast and oral cancer cells and organotypic tumor slice culture
10.1021/acsomega.6c02787 · doi-reference
Beyond FOXO1: AS1842856 inhibits GSK3 to enhance cytotoxic effects in B-ALL
10.1182/bloodadvances.2024015560 · doi-reference
NB compounds are potent and efficacious FOXM1 inhibitors in high-grade serous ovarian cancer cells
10.1186/s13048-024-01421-4 · doi-reference
Suppression of FOXM1 activities and breast cancer growth in vitro and in vivo by a new class of compounds
10.1038/s41523-019-0141-7 · doi-reference
Suppression of the FOXM1 transcriptional programme via novel small molecule inhibition
10.1038/ncomms6165 · doi-reference
Molecular dynamics simulations of human FOXO3 reveal intrinsically disordered regions spread spatially by intramolecular electrostatic repulsion
10.3390/biom11060856 · doi-reference
A drug repurposing study identifies novel FOXM1 inhibitors with in vitro activity against breast cancer cells
10.1007/s12032-024-02427-0 · doi-reference
Structure-based virtual screening identified novel FOXM1 inhibitors as the lead compounds for ovarian cancer
10.3389/fchem.2022.1058256 · doi-reference
Homology modeling, screening, and identification of potential FOXO6 inhibitors curtail gastric cancer progression: an in silico drug repurposing approach
10.1007/s12010-023-04490-1 · doi-reference
Homology modeling of Forkhead box protein C2: identification of potential inhibitors using ligand and structure-based virtual screening
10.1007/s11030-022-10519-0 · doi-reference
Highly accurate protein structure prediction with AlphaFold
10.1038/s41586-021-03819-2 · doi-reference
Targeting FOXM1 condensates reduces breast tumour growth and metastasis
10.1038/s41586-024-08421-w · doi-reference
Targeting transcription factors in cancer: from ‘undruggable’ to ‘druggable’
10.1007/978-1-0716-2815-7_9 · doi-reference
Intrinsically disordered proteins in cellular signalling and regulation
10.1038/nrm3920 · doi-reference
Intrinsic disorder in transcription factors
10.1021/bi0602718 · doi-reference
Small-molecule inhibitors targeting FOXM1: current challenges and future perspectives in cancer treatments
10.1016/j.bbcan.2023.189015 · doi-reference
Foxs1-mediated transformation of CD34+ fibroblast to myCAFs promotes tumor growth
10.1038/s44321-026-00476-8 · doi-reference
FOXJ1 mediates taxane resistance through regulation of microtubule dynamics
10.1038/s41467-026-69556-0 · doi-reference
The 2021 WHO classification of tumors of the central nervous system: a summary
10.1093/neuonc/noab106 · doi-reference
FOX transcription factors are common regulators of Wnt/β-catenin-dependent gene transcription
10.1016/j.jbc.2023.104667 · doi-reference
Co-regulation and function of FOXM1/ RHNO1 bidirectional genes in cancer
10.7554/elife.55070 · doi-reference
RHNO1: at the crossroads of DNA replication stress, DNA repair, and cancer
10.1038/s41388-024-03117-x · doi-reference
Suppression of FOXM1 sensitizes human cancer cells to cell death induced by DNA-damage
10.1371/journal.pone.0031761 · doi-reference
FOXM1 (Forkhead box M1) in tumorigenesis: overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumor-suppressive properties, and target of anticancer therapy
10.1016/b978-0-12-407190-2.00016-2 · doi-reference
The FOXM1-ABCC5 axis contributes to paclitaxel resistance in nasopharyngeal carcinoma cells
10.1038/cddis.2017.53 · doi-reference
Novel FOXM1 inhibitor STL001 sensitizes human cancers to a broad-spectrum of cancer therapies
10.1038/s41420-024-01929-0 · doi-reference
FOXM1 in cancer: interactions and vulnerabilities
10.1158/0008-5472.can-16-3566 · doi-reference